Stay updated with breaking news from Solid Tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug ...
Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Solid Tumor.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Beckman Coulter Life Sciences recently announced a collaboration agreement with Pillar Biosciences to forward NGS
Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.